...pregabalin or gabapentin for 4 weeks in 108 patients previously treated with pregabalin or gabapentin. Pharmaleads S.A.S....

...p=0.049 and p=0.0012, respectively). No opiate-type, central or peripheral adverse effects were reported. In 2008, Pharmaleads...
...PL37 to treat neuropathic pain and other chronic pain conditions (see BioCentury, Nov. 24, 2008). Pharmaleads...
...the deal was terminated in July 2011 due to a change in strategy at Debiopharm. Pharmaleads S.A.S....

...Debiopharm received exclusive, worldwide rights to develop and commercialize Pharmaleads' PL37 , now called Debio 0827...
...dual inhibitor of aminopeptidase and neutral endopeptidase will begin Phase I testing before year end. Pharmaleads...
...receive an undisclosed upfront payment and is eligible for milestones. Debiopharm S.A. , Lausanne, Switzerland Pharmaleads S.A.S....